Biosimilar FDA Meeting Types
It is crucial for biosimilar developers to engage early and often with FDA to ensure the health authority is well-informed and supports your planned...
Extending our scientific depth across allergy, dermatology, ophthalmology, respiratory, women's health, and more.
The development of biosimilar products in the U.S. has progressed since the regulatory pathway was established as part of the Affordable Care Act. Since then, the number of active biosimilar development programs has risen steadily. The market for these products is projected to exceed 100 billion dollars by 2028.
Listen to the full episode on Veristat’s Advancing Revolutionary Therapies Podcast to learn more about the analytical and clinical science of biosimilars and their regulatory pathway.
Learning Points
Meet Veristat. Learn More.
It is crucial for biosimilar developers to engage early and often with FDA to ensure the health authority is well-informed and supports your planned...
Mergers and acquisitions (M&As) are a defining feature of today’s biopharmaceutical landscape. As companies merge pipelines, teams, and strategies,...
Explore how Veristat guided a biotech firm through a clinical hold, ensuring smooth biologics development. Download our case study for vital insights.